高级检索
当前位置: 首页 > 详情页

Preventive effects of andrographolide on the development of diabetes in autoimmune diabetic NOD mice by inducing immune tolerance

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Dept Pharm, Tongji Hosp, Tongji Med Coll, Wuhan 430033, Peoples R China
出处:
ISSN:

关键词: Andrographolide Autoimmune diabetes Th1 Th2 Th17

摘要:
Andrographolide, an active component in traditional anti-diabetic herbal plants, is a diterpenoid lactone isolated from Andrographis paniculata because of its potent anti-inflammatory and hypoglycemic effects. However, the effect of andrographolide on the development of diabetes in autoimmune non-obese diabetic (NOD) mice remains unknown. This study aimed to investigate the protective effects of andrographolide on the development of autoimmune diabetes and clarify the underlying mechanism. NOD mice were randomly divided into four groups and administered with water and andrographolide at 50, 100, and 150 mg/kg body weight for four weeks. ICR mice were also selected as the control group. Oral glucose tolerance and histopathological insulitis were examined. Th1/Th2/Th17 cytokine secretion was determined by ELISA. The transcriptional profiles of T-bet, GATA3, and ROR gamma t in the pancreatic lymphatic node samples derived from the NOD mice were detected by RT-PCR. After four weeks of oral supplementation, andrographolide significantly inhibited insulitis, delayed the onset, and suppressed the development of diabetes in 30-week-old NOD mice in a dose dependent manner. This protective status was correlated with a substantially decreased production of interferon (IFN)-gamma and interleukin (IL)-2, increased IL-10 and transforming growth factor (TGF)-beta, and a reduced IL-17. Andrographolide also increased GATA3 mRNA expression but decreased T-bet and ROR gamma t mRNA expressions. Our results suggested that andrographolide prevented type 1 diabetes by maintaining Th1/Th2/Th17 homeostasis. (c) 2013 Elsevier B.V. All rights reserved.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 3 区 医学
小类 | 4 区 免疫学 4 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 药学 3 区 免疫学
JCR分区:
出版当年[2011]版:
Q2 PHARMACOLOGY & PHARMACY Q3 IMMUNOLOGY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Dept Pharm, Tongji Hosp, Tongji Med Coll, Wuhan 430033, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol, Dept Pharm, Tongji Hosp, Tongji Med Coll, Wuhan 430033, Peoples R China [*1]Huazhong Univ Sci & Technol, Dept Pharm, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:589 今日访问量:0 总访问量:441 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)